These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 32493233)
1. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233 [TBL] [Abstract][Full Text] [Related]
2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
3. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390 [TBL] [Abstract][Full Text] [Related]
4. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773 [TBL] [Abstract][Full Text] [Related]
5. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646 [TBL] [Abstract][Full Text] [Related]
6. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076 [TBL] [Abstract][Full Text] [Related]
7. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
8. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
10. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687 [TBL] [Abstract][Full Text] [Related]
11. Update on PARP Inhibitors in Breast Cancer. Zimmer AS; Gillard M; Lipkowitz S; Lee JM Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491 [TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL; Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262 [TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496 [TBL] [Abstract][Full Text] [Related]
14. BRCA1/2 testing: therapeutic implications for breast cancer management. Tung NM; Garber JE Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226 [TBL] [Abstract][Full Text] [Related]
15. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Kim DS; Camacho CV; Kraus WL Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630 [TBL] [Abstract][Full Text] [Related]
16. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122 [TBL] [Abstract][Full Text] [Related]
17. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Rabenau K; Hofstatter E Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114 [TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250 [TBL] [Abstract][Full Text] [Related]
20. Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives. Li XY; Chen JQ; Aisa A; Ding YW; Zhang D; Yuan Y J Dig Dis; 2023 Feb; 24(2):85-97. PubMed ID: 36987380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]